3-phthalimidopropane-N-methylsulfonamide | 859874-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-phthalimidopropane-N-methylsulfonamide
• 英文别名: N-methyl 3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propane-1-sulfonamide；3-(1,3-dioxoisoindol-2-yl)-N-methylpropane-1-sulfonamide
• CAS: 859874-13-8
• 化学式: C₁₂H₁₄N₂O₄S
• 分子量: 282.32
• InChiKey: SNDOBXIPPPNBRZ-UHFFFAOYSA-N

物化性质

• 沸点：
  459.4±47.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  91.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-phthalimidopropane-N-methylsulfonamide 在 乙醇 、 肼 、 盐酸 作用下， 以 水 为溶剂， 反应 5.83h， 生成 3-aminopropane-N-methylsulfonamide hydrochloride
  参考文献：
  名称：

  [EN] IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL, AND IMIDAZONAPHTHYRIDINYL SULFONAMIDES
  [FR] SULFONAMIDES D'IMIDAZOQUINOLINYLE, D'IMIDAZOPYRIDINYLE ET D'IMIDAZONAPHTYRIDINYLE

  摘要：

  公开号：

  WO2005066169A3
• 作为产物：
  描述：

  3(1,3-二氧-1,3-二氢-2H-异吲哚-2-基)丙烷-1-磺酰氯 、 甲胺 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 3-phthalimidopropane-N-methylsulfonamide
  参考文献：
  名称：

  [EN] IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL, AND IMIDAZONAPHTHYRIDINYL SULFONAMIDES
  [FR] SULFONAMIDES D'IMIDAZOQUINOLINYLE, D'IMIDAZOPYRIDINYLE ET D'IMIDAZONAPHTYRIDINYLE

  摘要：

  公开号：

  WO2005066169A3

文献信息

• Quinazolines and related heterocyclic compounds and their therapeutic use
  申请人：Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg

  公开号：EP2077263A1

  公开（公告）日：2009-07-08

  A compound of the formula wherein X is CR1 or N; Y is CR3 or N; R1, R3, R4, R5 and R6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R7 is a heterocyclic group including one or more N atoms; R' is Rx or NRyRz wherein Rx, Ry and Rz are each H or the same or different groups, including cyclic groups formed by Ry and Rz with the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof, has therapeutic utility.

  该化合物的公式为X是CR1或N；Y是CR3或N；R1、R3、R4、R5和R6分别独立地为H、F、Cl、Br、I或一个可能含有一个或多个杂原子的碳氢基团；R7是一个包括一个或多个N原子的杂环基团；R'是Rx或NRyRz，其中Rx、Ry和Rz分别为H或相同或不同的基团，包括由Ry和Rz与N原子形成的环基团，最多包含20个碳原子，且可选地包含最多3个进一步从N、O和S中选择的杂原子；或其药用盐、酯或溶剂化合物具有治疗用途。
• Therapeutic Agent for Restenosis
  申请人：Nakai Ryuichiro

  公开号：US20100029625A1

  公开（公告）日：2010-02-04

  A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, R 0 represents aryl, —NR 1 CONR 2 (wherein R 1 represents a hydrogen atom or the like, and R 2 represents lower alkyl or the like) or the like, R 3 represents lower alkyl, R 4 represents a hydrogen atom or the like, and R 5 represents aryl or the like].

  治疗和/或预防再狭窄的治疗剂和/或预防剂，包括由下式所表示的噻二唑啉衍生物或其药学上可接受的盐：[式中，n代表1到3的整数，R0代表芳基，—NR1CONR2（其中R1代表氢原子或类似物，R2代表低碳基或类似物）或类似物，R3代表低碳基，R4代表氢原子或类似物，R5代表芳基或类似物]。
• Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
  申请人：Smits Rogier Adriaan

  公开号：US20100298322A1

  公开（公告）日：2010-11-25

  A compound of the formula (I) wherein X is CR 1 or N; Y is CR 3 or N; R 1 , R 3 , R 4 , R 5 and R 6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R 7 is a heterocyclic group including one or more N atoms; R′ is R x or NR y R z wherein R x , R y and R z are each H or the same or different groups, including cyclic groups formed by R y and R z with the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof.

  化合物的式子 (I)，其中 X 是 CR1 或 N；Y 是 CR3 或 N；R1、R3、R4、R5 和 R6 分别是 H、F、Cl、Br、I 或一个含有一个或多个杂原子的碳氢基团；R7 是一个含有一个或多个 N 原子的杂环基团；R′ 是 Rx 或 NRyRz，其中 Rx、Ry 和 Rz 分别是 H 或相同或不同的基团，包括由 Ry 和 Rz 与 N 原子形成的环状基团，具有高达 20 个 C 原子并且可选地包括最多 3 个来自 N、O 和 S 的进一步杂原子；或其药学上可接受的盐、酯或溶剂化物。
• Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H₄ Receptor Inverse Agonists
  作者：Rogier A. Smits、Maristella Adami、Enade P. Istyastono、Obbe P. Zuiderveld、Cindy M. E. van Dam、Frans J. J. de Kanter、Aldo Jongejan、Gabriella Coruzzi、Rob Leurs、Iwan J. P. de Esch

  DOI：10.1021/jm901379s

  日期：2010.3.25

  Hit optimization of the class of quinazoline containing histamine H-4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (54) (pK(i) = 8.31 +/- 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.
• Quinazolines and related heterocyclic compounds, and their therapeutic use
  申请人：Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg

  公开号：EP2238119B1

  公开（公告）日：2015-11-25